Journal article
Both high-dose (4.8g/day) induction and low-dose (2.4g/day) maintenancetherapy with MMXTM mesalamine have an excellent safety profile in patients with mild-to-moderate ulcerative colitis
G Lichtenstein, W Sandborn, M Kamm, K Barrett, R Joseph
Inflammatory Bowel Diseases | Oxford University Press (OUP) | Published : 2008